Troutman Sanders Advises Antios Therapeutics Inc. in Hepatitis Drug Financing
ATLANTA – Troutman Sanders LLP recently advised Antios Therapeutics Inc., a biopharmaceutical company focused on the development of novel antiviral therapies for unmet medical needs, in the completion of $25 million oversubscribed Series A financing led by Lumira Ventures and Domain Associates, two prominent life science venture capital firms. Proceeds from the financing will be used to develop ATI-2173, Antios' lead oral drug candidate for treating patients infected with Hepatitis B virus (HBV) and potentially Hepatitis D virus (HDV).
"The next frontier in virology is to cure Hepatitis B. At Antios, we are committed to this pursuit," said co-founder and Chief Executive Officer, Abel De La Rosa, Ph.D in a press release. "The strong financial support from our investors along with their extensive experience in clinical development and success building innovative companies in the infectious disease field will enable us to accelerate the development of ATI-2173 as a potential backbone of therapy to cure HBV."
The Troutman Sanders team on the matter was led by corporate attorneys Brendan Thomas (Atlanta) and Bardia Moayedi (San Diego/Orange County).
Troutman Sanders has a robust Emerging Growth Company and Venture Capital practice, assisting numerous start-ups through various stages of financing and venture capital firms, as well as the venture arms of operating companies, execute their investment strategies.
About Antios Therapeutics Inc.
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate
for a potentially curative treatment of HBV infections.
About Troutman Sanders
With a diverse practice mix, workforce and footprint, Troutman Sanders has cultivated its reputation for a higher commitment to client care for over 120 years. Ideally positioned to help clients across sectors realize their business
goals, the firm’s 650 attorneys transact for growth, resolve mission-threatening disputes and navigate complex legal and regulatory challenges. See
troutman.com for more information.